DERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:

Size: px
Start display at page:

Download "DERBY-BURTON CANCER NETWORK CONTROLLED DOC NO:"

Transcription

1 OBINUTUZUMAB+CHLORAMBUCIL Regimen RDH; Day 1 and 2 Dose to be given on Ward Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication First line treatment of CLL in patients unsuitable for full dose fludarabine and bendamustine Treatment Intent Palliative Anti-Emetics Pre-chemotherapy 1 Post-chemotherapy A Frequency & Every 28 days for up to 6 cycles Duration CYCLE 1 ONLY Day 1 Sodium chloride 500ml Intravenous infusion over 30 minutes 0.9% Dexamethasone 20mg Slow intravenous injection 60 minutes pre Chlorphenamine 4mg Orally as a single dose 30 minutes pre Paracetamol 1g Orally as a single dose 30 minutes pre Pethidine 25mg Intravenous injection if required for severe rigors Obinutuzumab 100mg Intravenous infusion in 100ml sodium chloride 0.9% over 4 hours. Do not increase the infusion rate. Chlorambucil 0.5mg/kg Orally as a single dose (Rounded to nearest 2mg) Allopurinol 300mg Oral once daily for 28 days for 1-2 cycles or as clinically indicated Aciclovir 400mg Oral twice daily for 28 days Co-trimoxazole 480mg Oral once daily for 28 days Metoclopramide 10mg Oral four times daily as required Day 2 Sodium 500ml Intravenous infusion over 30 minutes chloride0.9% Dexamethasone 20mg Slow intravenous injection 60 minutes pre Chlorphenamine 4mg Orally as a single dose 30 minutes pre Paracetamol 1g Orally as a single dose 30 minutes pre AUTHORISED BY: Dr J Addada PAGE 1 of 10

2 Days 8 & 15 Day 15 ONLY Pethidine 25mg Intravenous injection if required for severe rigors Obinutuzumab 900mg Intravenous infusion in 250ml sodium chloride 0.9% as per rate calculator Sodium chloride 500ml Intravenous infusion over 30 minutes 0.9% Dexamethasone 20mg Slow intravenous injection 60 minutes pre Obinutuzumab For patients with a previous Grade 3 reaction or lymphocyte count >25x10 9 /I ONLY Chlorphenamine 4mg Orally as a single dose 30 minutes pre Obinutuzumab Paracetamol 1g Orally as a single dose 30 minutes pre Obinutuzumab Pethidine 25mg Intravenous injection if required for severe rigors Obinutuzumab 1000mg Intravenous infusion in 250ml sodium chloride 0.9% as per rate calculator Chlorambucil 0.5mg/kg Orally as a single dose (rounded to nearest 2mg) CYCLES 2-6 Day 1 Sodium chloride 500ml Intravenous infusion over 30 minutes 0.9% Dexamethasone 20mg Slow intravenous injection 60 minutes pre For patients with a previous Grade 3 reaction or lymphocyte count >25x10 9 /l ONLY Chlorphenamine 4mg Orally as a single dose 30 minutes pre Paracetamol 1g Orally as a single dose 30 minutes pre Pethidine 25mg Intravenous injection if required for severe rigors Day 1 Obinutuzumab Chlorambucil 1000mg 0.5mg/kg Intravenous infusion in 250ml sodium chloride 0.9% Orally as per a single rate calculator dose & 15 (Rounded to nearest 2mg) Allopurinol Aciclovir 300mg 400mg Oral once daily for 28 days for 1-2 cycles or as clinically Oral twice indicated daily for 28 days Co-trimoxazole 480mg Oral once daily for 28 days AUTHORISED BY: Dr J Addada PAGE 2 of 10

3 Metoclopramide 10mg Oral four times daily as required The following rescue medicines to be prescribed/available for infusion reactions: Paracetamol 1g Oral/IV (max 4g in 24 hours) Chlorphenamine 10mg IV (max 4 doses in 24 hours) Dexamethasone 20mg IV for severe infusion reactions Notes: Baseline investigations Cardiac tests for patients with cardiac risk factors Hepatitis B serology FBC, U&Es, LFTs Consider uric acid and bone profile for patients at risk of tumour lysis Patients who have pre-existing cardiac or pulmonary conditions should be monitored carefully throughout the infusion and the post-infusion period. Hypotension may occur during intravenous infusions. Therefore, withholding of antihypertensive treatments should be considered for 12 hours prior to and throughout each infusion and for the first hour after administration. Patients at acute risk of hypertensive crisis should be evaluated for the benefits and risks of withholding their anti-hypertensive medicine Investigations during each cycle FBC before each dose and as clinically indicated following treatment completion U&Es & LFTs prior to Day 1 and 15 and as clinically indicated Tumour lysis bloods as clinically indicated Toxicity assessment at each visit for infusion related reactions, infection, bleeding, thromboembolism, GI, cardiac and respiratory effect AUTHORISED BY: Dr J Addada PAGE 3 of 10

4 Dose modifications and toxicities 1. Haematological toxicity Toxicity Obinutuzumab Dose Chlorambucil Dose Grade 3 or 4 haematological toxicity, febrile neutropenia or thrombocytopaenic bleeding Grade 3 or 4 haematological toxicity that delays treatment by >4 weeks Toxicity Hold until the above parameters are met then restart at usual dose AUTHORISED BY: Dr J Addada PAGE 4 of 10 (% of previous dose) Hold until the above parameters are met. 1st episode: upon recovery restart at 75% 2nd episode: upon recovery restart at 50% 3rd episode: discontinue At the start of each cycle the neutrophil count should be 1.5 x 10 9 /l and platelets 100 x 10 9 /l (unsupported) unless cytopaenias are considered to be diseaserelated. 2. Non-haematological toxicity Grade 2 or 3 related organ/nonhaematological toxicity grade 2 non haematological toxicity that delays treatment by >4 weeks Grade 4 related organ/nonhaematological toxicity, severe haemorrhage, severe skin reaction, pneumonitis, severe arrhythmias or other severe cardiovascular events Viral hepatitis or other serious infections; reactivation of hepatitis B Obinutuzumab dose Chlorambucil dose (% previous dose) Hold until grade 1 Hold until grade 1 3. Infusion related reactions (IRR) and hypersensitivity reactions Infusion related reactions occurred in the majority of patients during the first cycle in the pivotal study. Patients with a high tumour burden (i.e. high peripheral lymphocyte count > 25 x 10 9 /L) may be at increased risk of severe infusion related reactions. Owing to the risk of infusion related reactions, consideration should be given to administering cycle 1 days 1 & 2 as an inpatient stay. Most frequently reported symptoms associated with an IRR were nausea, chills, hypotension, pyrexia, vomiting, dyspnoea, flushing, hypertension, headache, tachycardia, and diarrhoea. Respiratory and cardiac symptoms such as bronchospasm, larynx and throat irritation, wheezing, laryngeal oedema and atrial fibrillation have also been reported.

5 Anaphylaxis has been reported in patient. If a hypersensitivity reaction is suspected during infusion (e.g. symptoms typically occurring after previous exposure and very rarely with the first infusion), the infusion must be stopped and treatment permanently discontinued. Appropriate pre-medication must be administered before each infusion to reduce the risk of IRRs Toxicity Obinutuzumab dose Chlorambucil Dose (% of previous dose) Grade 1-2 infusion 1 st episode of grade 3 infusion reaction Reduce infusion rate by half and treat symptoms. Restart once resolved. Escalate infusion rate as tolerated at increments appropriate for treatment Hold infusion and treat symptoms. Restart once resolved at no more than half the previous rate. Escalate infusion rate as tolerated at increments appropriate for the treatment dose (See below) The Day 1 (Cycle 1) infusion rate may be increased back up to 25 mg/hr after 1 hour, but not increased further No change No change 2nd episode of grade 3 infusion reaction (during same or subsequent infusion) Grade 4 infusion reaction or acute life threatening respiratory reactions Infusion must be stopped and therapy must be permanently discontinued Infusion must be stopped and therapy must be permanently discontinued (Refer to table1 at the end of this document for grading of reactions) AUTHORISED BY: Dr J Addada PAGE 5 of 10

6 4. Standard infusion rate in the absence of infusion reactions or hypersensitivity ycycle Day of Treatment Rate of Infusion Cycle 1 Cycle 1 Day 1 (100mg in 100ml) Day 2 (or day 1 continued) (900mg in 250 ml) Administer at 25 mg/hr over 4 hours. Do not increase the infusion Administer rate. 50 mg/hr. Cycle 1 Day 8 & 15 (1000mg in 250ml) Cycles 2-6 All days (1000mg in 250ml) The rate of the infusion can be escalated in increments of 50 mg/hr every 30 minutes to a maximum rate of 400 mg/hr Infusions can be started at a rate of 100 mg/hr and increased by 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. Infusions can be started at a rate of 100 mg/hr An and increased by 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. See associated rate calculator to support administration Cycle 1 - the recommended dose of is 1000 mg administered over Day 1 and Day 2, and on Day 8 and Day 15 of the first 28 day treatment cycle. Two infusion bags should be prepared for the infusion on Days 1 and 2 (100 mg for Day 1 and 900 mg for Day 2). If the first infusion (100mg) is completed without modifications of the infusion rate or interruptions, the second bag may be administered on the same day (no dose delay necessary, no repetition of premedication), provided that appropriate time, conditions and medical supervision are available throughout the infusion. If there are any modifications of the infusion rate or interruptions during the first 100 mg the second infusion (900mg) must be administered the following day. Management of IRRs may require temporary interruption, reduction in the rate of infusion, or treatment discontinuations of as outlined below (see also SPC). Grade 4 (life threatening): Infusion must be stopped and therapy must be permanently discontinued. Grade 3 (severe): Infusion must be temporarily stopped and symptoms treated. Upon resolution of symptoms, the infusion can be restarted at no more than half the previous rate (the rate being used at the time that the IRR occurred) and, if the patient does not experience any IRR symptoms, the infusion rate escalation can resume at the increments and intervals as appropriate for the treatment dose (see table above). The Day 1 (Cycle 1) infusion rate may be increased back up to 25 mg/hr after 1 hour, but not increased further. The infusion must be stopped and therapy permanently discontinued if the patient experiences a second occurrence of a Grade 3 IRR 5. Renal Impairment In the pivotal trial, patients with moderate renal impairment (CrCl < 50 ml/min) experienced more serious adverse events than those with CrCl 50 ml/min AUTHORISED BY: Dr J Addada PAGE 6 of 10

7 CrCl (ml/min) Obinutuzumab dose Chlorambucil Dose (% of previous dose) >30 but <50 No change, use with caution 75% 10 to 30 No data, omit 75% <10 No data, omit 50% 6. Hepatic impairment Safety and efficacy of have not been established in patients with hepatic impairment. For chlorambucil, dose adjustment is required with severe hepatic impairment; no details found. Modify dose according to response 7. Other adverse effects Cardiac effects Patients who have pre-existing cardiac or pulmonary conditions should be monitored carefully throughout the infusion and the post-infusion period. Hypotension may occur during infusions. Therefore, withholding of antihypertensive treatments should be considered for 12 hours prior to and throughout each infusion and for the first hour after administration. In patients with underlying cardiac disease, arrhythmias, angina pectoris, acute coronary syndrome, myocardial infarction and heart failure have occurred. Therefore patients with a history of cardiac disease should be monitored closely. Thrombocytopaenia Severe and life-threatening thrombocytopenia including acute thrombocytopenia (occurring within 24 hours after the infusion) has been observed during treatment. Patients with renal impairment (CrCl < 50 ml/min) are more at risk of thrombocytopenia. Haemorrhagic events have also been reported. Patients should be closely monitored for thrombocytopenia, especially during the first cycle. Use of antiplatelets and anticoagulants, which could possibly worsen thrombocytopenia- related events should also be taken into consideration, especially during the first cycle. AUTHORISED BY: Dr J Addada PAGE 7 of 10

8 PML Progressive multifocal leukoencephalopathy (PML) has been reported in patients treated with. The diagnosis of PML should be considered in any patient presenting with new-onset or changes to preexisting neurologic manifestations. The patient should be referred to a neurologist for the evaluation and treatment of PML. 8. Drug interactions None known. Vaccination with live virus vaccines is not recommended during treatment and until B cell recovery because of the immunosuppressive effect of Supportive care 1. Tumour lysis syndrome Patients with a high tumour burden and/or a high circulating lymphocyte count [> 25 x 10 9 /L] and/or renal impairment [CrCl <70 ml/min]) should receive prophylaxis with adequate hydration and administration of allopurinol, or rasburicase starting hours prior to the infusion. Renal function, potassium, and uric acid should be monitored carefully in the initial days after treatment 2. Anti-infective prophylaxis All patients should receive: Co-trimoxazole 480mg once daily. o In cases of allergy to cotrimoxazole consider dapsone 100mg daily. Aciclovir 400mg twice daily. Consider antifungal prophylaxis with Fluconazole 100mg daily if prolonged neutropaenia occurs until neutrophils >1x10 9 /l References 1. NICE technology appraisal guidance [TA343]; Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia; Published date: June Gazyvaro Summary of Product Characteristics; Last Updated on emc 19-Jun-2015 (Accessed 13/8/2015) 3. Cancer Care Ontario Chlo+Obin regimen monograph Jan The North London Cancer Network. Dosage Adjustments for Cytotoxics in Hepatic Impairment. November 2003 AUTHORISED BY: Dr J Addada PAGE 8 of 10

9 6. The North London Cancer Network. Dosage Adjustments for Cytotoxics in Renal Impairment. November 2003 AUTHORISED BY: Dr J Addada PAGE 9 of 10

10 Table 1. NCI-CTCAE Grading of infusion related reactions and hypersensitivity reactions Adverse event Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Allergic Anaphylaxis Death reaction/hypersensitivity Cytokine release syndrome/infusion related reaction Transient flushing or rash, fever <38 C Mild reaction; infusion interruption not indicated; intervention not indicated Rash: flushing; urticaria; dyspnoea; drug fever 38 C Requires infusion interruption but responds promptly to symptomatic treatment (e.g., antihistamines, IV fluids); prophylactic medications indicated for <=24 hrs Symptomatic bronchospasm, with or without urticaria; parenteral medications indicated; allergy related oedema/angioedema; hypotension Prolonged (e.g. not rapidly responsive to symptomatic medication and/or brief interruption of infusion) recurrence of symptoms following initial improvement; hospitalization indicated (e.g., renal impairment, pulmonary infiltrates) Life-threatening consequences; pressor or ventilatory support indicated Death PAGE 10 of AUTHORISED BY: Dr J Addada 10

Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case

Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case Obinutuzumab+Bendamustine followed by Obinutuzumab Maintenance Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Available

More information

Note: There are other bendamustine protocols, ensure this is the correct one for a given patient.

Note: There are other bendamustine protocols, ensure this is the correct one for a given patient. INDICATIONS 1 st line treatment for follicular lymphoma with FLIPI score 2 or higher: (NICE TA513- BLUETEQ required) Rituximab refractory follicular lymphoma (progression on R-chemo, R-maintenance or within

More information

R-BAC-500 (Rituximab, Bendamustine, Cytarabine) for Mantle Cell Lymphoma

R-BAC-500 (Rituximab, Bendamustine, Cytarabine) for Mantle Cell Lymphoma R-BAC-500 (Rituximab, Bendamustine, Cytarabine) for Mantle Cell Lymphoma Not routinely commissioned, each case requires prior documented approval before offering & commencing therapy from NHS England Cancer

More information

Fludarabine + Cyclophosphamide + Rituximab (FCR) - FLAIR Study

Fludarabine + Cyclophosphamide + Rituximab (FCR) - FLAIR Study Fludarabine + Cyclophosphamide + Rituximab (FCR) - FLAIR Study Front-Line therapy in CLL: Assessment of Ibrutinib-containing Regimes. ***See protocol for further details*** Available for Routine Use in

More information

NCCP Chemotherapy Regimen. Obinutuzumab and Chlorambucil Therapy

NCCP Chemotherapy Regimen. Obinutuzumab and Chlorambucil Therapy INDICATIONS FOR USE: Obinutuzumab INDICATION ICD10 Regimen Code *Reimbursement Indicator Treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities

More information

O-CVP with maintenance Obinutuzumab

O-CVP with maintenance Obinutuzumab with maintenance Obinutuzumab INDICATION Follicular Lymphoma: 1 st line treatment in advanced symptomatic patients (NICE TA513 for FLIPI score 2 or higher - BLUETEQ required) TREATMENT INTENT Disease modification.

More information

O-CHOP with Obinutuzumab maintenance

O-CHOP with Obinutuzumab maintenance O-CHOP with Obinutuzumab maintenance Indication Adult patients with untreated advanced follicular lymphoma with Follicular Lymphoma International Prognostic Index (FLIPI) score of 2 or above. (NICE TA513)

More information

Guidelines for the administration of Rituximab

Guidelines for the administration of Rituximab the administration of 1. Introduction Administration of the anti-cd20 monoclonal antibody is associated with severe hypersensitivity reactions, potentially life threatening cytokine release syndrome, and

More information

NCCP Chemotherapy Regimen. Obinutuzumab Maintenance Therapy following O-Bendamustine therapy

NCCP Chemotherapy Regimen. Obinutuzumab Maintenance Therapy following O-Bendamustine therapy Obinutuzumab following O-Bendamustine therapy INDICATIONS FOR USE: INDICATION Obinutuzumab maintenance therapy is indicated in patients with follicular lymphoma (FL) who have responded to induction treatment

More information

GAZYVA Dosing and Administration Guide

GAZYVA Dosing and Administration Guide GAZYVA Dosing and Administration Guide Indications GAZYVA is a CD20-directed cytolytic antibody and is indicated: In combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at

More information

Docetaxel + Nintedanib

Docetaxel + Nintedanib Docetaxel + Nintedanib Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Second

More information

Rituximab, Gemcitabine, Dexamethasone and Cisplatin RGDP Regimen

Rituximab, Gemcitabine, Dexamethasone and Cisplatin RGDP Regimen Rituximab, Gemcitabine, Dexamethasone and Cisplatin RGDP Regimen Available for Routine Use in Burton in-patient N/A Derby in-patient Burton day-case Derby day-case Burton outreach chemotherapy clinic N/A

More information

R-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement)

R-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement) R-ICE Regimen- Rituximab, Etoposide, Ifosfamide (with MESNA), Carboplatin (+ Depocyte if CNS involvement) Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case

More information

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-GCVP.DOC CONTROLLED DOC NO: HCCPG B12 CSIS Regimen Name: R-GCVP. R-GCVP Regimen

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-GCVP.DOC CONTROLLED DOC NO: HCCPG B12 CSIS Regimen Name: R-GCVP. R-GCVP Regimen R-GCVP Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication CD 20 positive

More information

DERBY-BURTON LOCAL CANCER NETWORK FILENAME Peruse.DOC CONTROLLED DOC NO: CCPG R29

DERBY-BURTON LOCAL CANCER NETWORK FILENAME Peruse.DOC CONTROLLED DOC NO: CCPG R29 Pertuzumab + Trastuzumab + Docetaxel (Peruse study) A Multicenter, open-label, single arm study of Pertuzumab in combination with Trastuzumab and a Taxane in first-line treatment of patients with HER2-positive

More information

Gemcitabine + Capecitabine (ESPAC-4 Trial)

Gemcitabine + Capecitabine (ESPAC-4 Trial) Gemcitabine + Capecitabine (ESPAC-4 Trial) European Study Group For Pancreatic Cancer - Trial 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and ampullary cancers. ***

More information

IBRUTINIB + Rituximab, Treatment Period - ENRICH Study

IBRUTINIB + Rituximab, Treatment Period - ENRICH Study IBRUTINIB + Rituximab, Treatment Period - Study Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma ***See protocol for further

More information

Rituximab (weekly) for Primary Cutaneous B cell Lymphoma

Rituximab (weekly) for Primary Cutaneous B cell Lymphoma Rituximab (weekly) for Primary Cutaneous B cell Lymphoma Indication: Palliative therapy for Low grade Primary Cutaneous B cell Lymphoma (Primary cutaneous Follicle centre cell Lymphoma and Primary cutaneous

More information

Summary of the risk management plan (RMP) for Gazyvaro (obinutuzumab)

Summary of the risk management plan (RMP) for Gazyvaro (obinutuzumab) EMA/319729/2014 Summary of the risk management plan (RMP) for Gazyvaro (obinutuzumab) This is a summary of the risk management plan (RMP) for Gazyvaro, which details the measures to be taken in order to

More information

Durvalumab (previously known as MEDI 4736) Maintenance (Arm A3) PLATFORM study

Durvalumab (previously known as MEDI 4736) Maintenance (Arm A3) PLATFORM study Durvalumab (previously known as MEDI 4736) Maintenance (Arm A3) PLATFORM study PLAnning Treatment For Oesophago-gastric cancer: a Randomised Maintenance therapy trial. ***See Protocol for further details***

More information

Rituximab-CHOP Regimen - ENRICH Study

Rituximab-CHOP Regimen - ENRICH Study Rituximab-CHOP Regimen - Study Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma ***See protocol for further details***

More information

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection

MabThera. SC. The wait is over. MabThera delivered in just 5 minutes. SC= subcutaneous injection MabThera SC. The wait is over. MabThera delivered in just 5 minutes Abbreviated Prescribing Information MabThera 1400 mg solution for subcutaneous (SC) injection (Rituximab) Indications: Indicated in adults

More information

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-IVE.DOC CONTROLLED DOC NO: HCCPG B53 CSIS Regimen Name: R-IVE. R-IVE Regimen

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-IVE.DOC CONTROLLED DOC NO: HCCPG B53 CSIS Regimen Name: R-IVE. R-IVE Regimen R-IVE Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Relapsed/ refractory

More information

Gemcitabine, Dexamethasone and Cisplatin GDP Regimen

Gemcitabine, Dexamethasone and Cisplatin GDP Regimen Gemcitabine, Dexamethasone and Cisplatin GDP Regimen Available for Routine Use in Burton in-patient N/A Derby in-patient Burton day-case Derby day-case Burton outreach chemotherapy clinic N/A Derby outreach

More information

RiTUXimab 375 mg/m 2 Therapy-7 day

RiTUXimab 375 mg/m 2 Therapy-7 day RiTUXimab 375 mg/m 2 Therapy-7 day This regimen supercedes NCCP Regimen 00208 rituximab 375mg/m2 therapy-follicular lymphoma as of February 2019 INDICATIONS FOR USE: Regimen *Reimbursement INDICATION ICD10

More information

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-CODOX-M.DOC CONTROLLED DOC NO: HCCPG B115 CSIS Regimen Name: R-CODOXM. Rituximab + CODOX-M

DERBY-BURTON LOCAL CANCER NETWORK FILENAME R-CODOX-M.DOC CONTROLLED DOC NO: HCCPG B115 CSIS Regimen Name: R-CODOXM. Rituximab + CODOX-M Rituximab + CODOX-M Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Burkitt

More information

Skin Pathway Group Alemtuzumab in Cutaneous Lymphoma

Skin Pathway Group Alemtuzumab in Cutaneous Lymphoma Skin Pathway Group Alemtuzumab in Cutaneous Lymphoma Indication: Treatment of patients with Cutaneous Lymphoma (Unlicensed use) Disease control prior to Reduced Intensity Conditioning Stem Cell Transplant

More information

Subcutaneous Rituximab with or without Ibrutinib, Maintenance Period - ENRICH Study

Subcutaneous Rituximab with or without Ibrutinib, Maintenance Period - ENRICH Study Subcutaneous Rituximab with or without Ibrutinib, Maintenance Period Study Randomised, open label study of Rituximab/Ibrutinib vs Rituximab/Chemotherapy in older patients with untreated mantle cell lymphoma

More information

R-Gemcitabine (1000mg/m 2 ) Oxaliplatin Therapy i - 14 day

R-Gemcitabine (1000mg/m 2 ) Oxaliplatin Therapy i - 14 day R-Gemcitabine (1000mg/m 2 ) Oxaliplatin i - 14 day INDICATIONS FOR USE: Regimen Code INDICATION ICD10 Relapsed or refractory CD20 positive diffuse large B cell lymphoma in patients ineligible for stem

More information

E 90 C followed by Weekly Paclitaxel

E 90 C followed by Weekly Paclitaxel E 90 C followed by Weekly Paclitaxel Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient

More information

SUBCUTANEOUS Bortezomib + Thalidomide +Dexamethasone Available for Routine Use in

SUBCUTANEOUS Bortezomib + Thalidomide +Dexamethasone Available for Routine Use in SUBCUTANEOUS Bortezomib + Thalidomide +Dexamethasone Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby

More information

Docetaxel + Carboplatin + Trastuzumab

Docetaxel + Carboplatin + Trastuzumab Docetaxel + Carboplatin + Trastuzumab Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient

More information

Dosing and Administration Guide for ARZERRA

Dosing and Administration Guide for ARZERRA Dosing and Administration Guide for ARZERRA INDICATIONS for ARZERRA (ofatumumab) In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL)

More information

Carfilzomib and Dexamethasone (CarDex)

Carfilzomib and Dexamethasone (CarDex) Carfilzomib and Dexamethasone (CarDex) Indication Relapsed multiple myeloma for patients who have had only one previous line of therapy (that did not include bortezomib). (NICE TA457) ICD-10 codes Codes

More information

Breast Pathway Group Bevacizumab & Paclitaxel in Advanced Breast Cancer

Breast Pathway Group Bevacizumab & Paclitaxel in Advanced Breast Cancer Breast Pathway Group Bevacizumab & Paclitaxel in Advanced Breast Cancer Indication: First-line or second-line treatment of triple negative advanced breast cancer National Cancer Drug Fund criteria: Advanced

More information

Dosing and Administration Guide for ARZERRA

Dosing and Administration Guide for ARZERRA Dosing and Administration Guide for ARZERRA Indications ARZERRA (ofatumumab) is indicated: In combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic

More information

Idelalisib and RiTUXimab Therapy INDICATIONS FOR USE: EXCLUSIONS: Hypersensitivity to idelalisib, rituximab or any of the excipients.

Idelalisib and RiTUXimab Therapy INDICATIONS FOR USE: EXCLUSIONS: Hypersensitivity to idelalisib, rituximab or any of the excipients. INDICATIONS FOR USE: INDICATION In combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): who have received at least one prior therapy or as first line

More information

Bevacizumab + Paclitaxel & Carboplatin

Bevacizumab + Paclitaxel & Carboplatin Bevacizumab + Paclitaxel & Carboplatin Available for Routine Use in Not routinely commissioned, each case requires prior documented approval before offering & commencing therapy from NHS England Cancer

More information

Cisplatin / Paclitaxel Gynaecological Cancer

Cisplatin / Paclitaxel Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Cisplatin / Paclitaxel Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIP (Version No: 1.0) Approved for use in: First line treatment for stage Ib-IV with minimal residual

More information

Carboplatin + Paclitaxel Cancer of the Cervix

Carboplatin + Paclitaxel Cancer of the Cervix Carboplatin + Paclitaxel Cancer of the Cervix Background: Topotecan in combination with cisplatin is recommended as a treatment option for women with recurrent or stage IVB cervical cancer only if they

More information

Nordic Protocol (MaxiCHOP/R-MaxiCHOP plus R-HDAraC)

Nordic Protocol (MaxiCHOP/R-MaxiCHOP plus R-HDAraC) Nordic Protocol (MaxiCHOP/R-MaxiCHOP plus R-HDAraC) Available for Routine Use in Burton in-patient Derby in-patient (First cycle if bulky disease & risk of tumour lysis syndrome) Burton day-case Derby

More information

BC Cancer Protocol Summary for the Treatment of rituximabrefractory Follicular Lymphoma (FL) with obinutuzumab in combination with Bendamustine

BC Cancer Protocol Summary for the Treatment of rituximabrefractory Follicular Lymphoma (FL) with obinutuzumab in combination with Bendamustine BC Cancer Protocol Summary for the Treatment of rituximabrefractory Follicular Lymphoma (FL) with obinutuzumab in combination with Bendamustine Protocol Code Tumour Group Contact Physician ULYOBBEND Lymphoma

More information

BEVACIZUMAB (AVASTIN ) & Paclitaxel PROTOCOL

BEVACIZUMAB (AVASTIN ) & Paclitaxel PROTOCOL Bevacizumab (Avastin ) & Paclitaxel The treatment of Advanced Breast Cancer DRUG ADMINISTRATION Da Drug Daily Dose Route Diluent & Rate y 250mls Sodium Day 1,15 Bevacizumab 10 mg/kg Infusion Chloride 0.9%*

More information

Paclitaxel and Trastuzumab Breast Cancer

Paclitaxel and Trastuzumab Breast Cancer Systemic Anti Cancer Treatment Protocol Paclitaxel and Trastuzumab Breast Cancer PROTOCOL REF: MPHAPTRBR (Version No: 1.0) Approved for use in: HER2 positive breast cancer. For adjuvant use in T1 or T2

More information

DERBY-BURTON LOCAL CANCER NETWORK FILENAME CEOP.DOC CONTROLLED DOC NO: HCCPG B21 CSIS Regimen Name: CEOP. CEOP Regimen

DERBY-BURTON LOCAL CANCER NETWORK FILENAME CEOP.DOC CONTROLLED DOC NO: HCCPG B21 CSIS Regimen Name: CEOP. CEOP Regimen CEOP Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication T-cell non-hodgkin

More information

Carboplatin, Paclitaxel and Bevacizumab (gynae)

Carboplatin, Paclitaxel and Bevacizumab (gynae) Carboplatin, Paclitaxel and Bevacizumab (gynae) Indication First line treatment of recurrent or metastatic cervical cancer. WHO performance status 0 or 1. First line treatment of advanced epithelial ovarian,

More information

Breast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer

Breast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer Breast Pathway Group TC (Docetaxel / Cyclophosphamide) in Early Breast Cancer Indication: Neoadjuvant or adjuvant treatment for patients in whom anthracyclines are contraindicated or inappropriate Regimen

More information

Bevacizumab + Paclitaxel + Cisplatin

Bevacizumab + Paclitaxel + Cisplatin Bevacizumab + Paclitaxel + Cisplatin Available for Routine Use in Not routinely commissioned, each case requires prior documented approval before offering & commencing therapy from the Cancer Drugs Fund

More information

FLAG-Ida + Gemtuzumab Ozogamicin Regimen (Also known as FLAG-Ida + GO3x2) (AML19 Trial Course 1)

FLAG-Ida + Gemtuzumab Ozogamicin Regimen (Also known as FLAG-Ida + GO3x2) (AML19 Trial Course 1) FLAG-Ida + Gemtuzumab Ozogamicin Regimen (Also known as FLAG-Ida + GO3x2) (AML19 Trial Course 1) AML19 Adults with Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome ***Refer to trial protocol

More information

Ipilimumab in Melanoma

Ipilimumab in Melanoma Ipilimumab in Melanoma Indication: Advanced (unresectable or metastatic) melanoma in adults who have received prior therapy LCNDG criteria to be met: Histologically confirmed unresectable stage III or

More information

R-GemOx. Lymphoma group INDICATION. Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative

R-GemOx. Lymphoma group INDICATION. Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative R-GemOx INDICATION Relapsed or Refractory Lymphoma, for patients unsuitable for R-GDP regimen. Omit rituximab if CD20- negative TREATMENT INTENT Disease modification PRE-ASSESSMENT 1. Ensure histology

More information

FOLFIRINOX (pancreas)

FOLFIRINOX (pancreas) FOLFIRINOX (pancreas) Indication First or second line chemotherapy for metastatic pancreatic cancer. Eligible patients must be

More information

Lung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC) Lung Pathway Group Docetaxel & Carboplatin in Non- Small Cell Lung Cancer (NSCLC) Indication: First line palliative therapy for previously untreated Stage IIIB or IV NSCLC patients Regimen details: Docetaxel

More information

R-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes.

R-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes. R-IDARAM Indication Secondary CNS lymphoma ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 Rituximab 375mg/m 2 IV infusion 1 Methotrexate 12.5mg Intrathecal 1 Cytarabine 70mg

More information

Gemcitabine, Carboplatin and Bevacizumab (gynae)

Gemcitabine, Carboplatin and Bevacizumab (gynae) Gemcitabine, Carboplatin and Bevacizumab (gynae) Indication Second line advanced epithelial ovarian, fallopian tube or primary peritoneal cancer. WHO performance status 0 or 1. (Funding via the CDF) ICD-10

More information

Carboplatin / Gemcitabine Gynaecological Cancer

Carboplatin / Gemcitabine Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Carboplatin / Gemcitabine Gynaecological Cancer PROCTOCOL REF: MPHAGYNCAG (Version No: 1.0) Approved for use in: Recurrent/metastatic endometrial carcinoma Previously

More information

Oxaliplatin and Gemcitabine

Oxaliplatin and Gemcitabine Oxaliplatin and Gemcitabine Indication Palliative treatment for relapsed metastatic seminoma, non seminoma or combined tumours. ICD-10 codes Codes pre-fixed with C38, C48, C56, C62, C63, C75.3. Regimen

More information

High Dose Cytarabine plus high dose Methotrexate for CNS Lymphoma

High Dose Cytarabine plus high dose Methotrexate for CNS Lymphoma High Dose Cytarabine plus high dose Methotrexate for CNS Lymphoma Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton

More information

R-FC for Chronic Lymphocytic Leukaemia LKWOS-005/01

R-FC for Chronic Lymphocytic Leukaemia LKWOS-005/01 West of Scotland Cancer Network Chemotherapy Protocol R-FC for Chronic Lymphocytic Leukaemia LKWOS-005/01 Indication B cell Chronic Lymphocytic Leukaemia First line therapy in patients under 70 years of

More information

Fluorouracil, Oxaliplatin and Docetaxel (FLOT)

Fluorouracil, Oxaliplatin and Docetaxel (FLOT) Fluorouracil, Oxaliplatin and Docetaxel (FLOT) Indication Perioperative chemotherapy for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma. ICD-10 codes Codes with a prefix C15,C16 Regimen

More information

Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer

Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Indication: Neoadjuvant therapy for high risk and fit breast cancer patients suitable for

More information

Breast Pathway Group Docetaxel in Advanced Breast Cancer

Breast Pathway Group Docetaxel in Advanced Breast Cancer Breast Pathway Group Docetaxel in Advanced Breast Cancer Indication: First-line palliative treatment, with or without trastuzumab, for advanced breast cancer in patients for whom an anthracycline is not

More information

Capecitabine plus Docetaxel in Advanced Breast Cancer

Capecitabine plus Docetaxel in Advanced Breast Cancer Capecitabine plus Docetaxel in Advanced Breast Cancer Indication: Palliative therapy in Anthracycline-Pretreated Patients with Advanced Breast Cancer Regimen details: Docetaxel 75mg/m 2 IV D1 Capecitabine*

More information

BC Cancer Protocol Summary for Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and rituximab

BC Cancer Protocol Summary for Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and rituximab BC Cancer Protocol Summary for Treatment of Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia with Fludarabine and rituximab Protocol Code Tumour Group Contact Physicians LYCLLFLUDR Lymphoma Dr.

More information

ALL Phase 2 Induction (25-60 years)

ALL Phase 2 Induction (25-60 years) ALL Phase 2 (25-60 years) INDICATION of remission in Adult Acute Lymphoblastic Leukaemia (ALL) patients This protocol is suitable for patients aged 25-60 years. It may sometimes be used in older patients

More information

Antiemetic protocol for rare emetogenic chemotherapy - see protocol SCNAUSEA

Antiemetic protocol for rare emetogenic chemotherapy - see protocol SCNAUSEA BCCA Protocol Summary for Treatment of Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma with obinutuzumab and Chlorambucil Protocol Code Tumour Group Contact Physician

More information

Nivolumab and Ipilimumab

Nivolumab and Ipilimumab Nivolumab and Ipilimumab Indication Advanced (unresectable or metastatic) melanoma. (NICE TA400) ICD-10 codes Codes prefixed with C43 Regimen details Cycles 1-4 Nivolumab and Ipilimumab every 3 weeks Day

More information

Ipilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy.

Ipilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy. Ipilimumab (skin) Indication Advanced (unresectable or metastatic) melanoma in patients who have received prior therapy. (NICE TA268) ICD-10 codes Codes prefixed with C43 Regimen details Day Drug Dose

More information

BEVACIZUMAB in Ovarian cancer. Cancer drug fund application and approval is required for funding. Continue Bevacizumab treatment for up to 18 cycles.

BEVACIZUMAB in Ovarian cancer. Cancer drug fund application and approval is required for funding. Continue Bevacizumab treatment for up to 18 cycles. BEVACIZUMAB in Ovarian cancer Page 1 of 5 Indication: First line treatment in advanced (Stage IIIc/IV) ovarian cancer, either sub-optimally debulked at primary or delayed primary surgery, or not suitable

More information

CD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated

CD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated INDICATION CD20-positive high-grade non-hodgkin Lymphoma in patients in which R-CHOP is not indicated TREATMENT INTENT Curative or Disease Modification. PRE-ASSESSMENT 1. Ensure histology is confirmed

More information

NCCP Chemotherapy Regimen. Carfilzomib, Lenalidomide and Dexamethasone (KRd) Therapy - 28 day

NCCP Chemotherapy Regimen. Carfilzomib, Lenalidomide and Dexamethasone (KRd) Therapy - 28 day , Lenalidomide and Dexamethasone (KRd) Therapy - INDICATIONS FOR USE: INDICATION ICD10 Regimen Code Reimbursement Status *, lenalidomide and dexamethasone therapy is indicated for the treatment of adult

More information

Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic

More information

CARFILZOMIB /DEXAMETHASONE (CarDex)

CARFILZOMIB /DEXAMETHASONE (CarDex) CARFILZOMIB /DEXAMETHASONE (CarDex) INDICATIONS First Relapse multiple myeloma in bortezomib naïve patients [NICE TA457] Requires Blueteq Application TREATMENT INTENT Disease modification PRE-ASSESSMENT

More information

Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x 4 (3-weekly) in Early Breast Cancer

Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x 4 (3-weekly) in Early Breast Cancer Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x Indication: Neoadjuvant or adjuvant therapy for moderate to high risk node positive breast

More information

This is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21

This is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21 R- / INDICATION Lymphoma Histiocytosis Omit rituximab if CD20-negative. TREATMENT INTENT Disease modification or curative depending on clinical circumstances PRE-ASSESSMENT 1. Ensure histology is confirmed

More information

Liposomal Doxorubicin (CAELYX) Gynaecological Cancer

Liposomal Doxorubicin (CAELYX) Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Liposomal Doxorubicin (CAELYX) Gynaecological Cancer PROCTOCOL REF: OPHAGYNCAE (Version No: 1.0) Approved for use in: Advanced ovarian cancer second/third line treatment

More information

DERBY-BURTON LOCAL CANCER NETWORK FILENAME SMILE.DOC CONTROLLED DOC NO: HCCPG B57 CSIS Regimen Name: SMILE. SMILE chemotherapy

DERBY-BURTON LOCAL CANCER NETWORK FILENAME SMILE.DOC CONTROLLED DOC NO: HCCPG B57 CSIS Regimen Name: SMILE. SMILE chemotherapy SMILE chemotherapy Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Extranodal

More information

Carboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer

Carboplatin / Liposomal Doxorubicin CARBO/CAELYX Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Carboplatin / CARBO/CAELYX Gynaecological Cancer PROCTOCOL REF: MPHAGYNCCX (Version No: 1.0) Approved for use in: Advanced ovarian cancer in women who have progressed

More information

Fludarabine-Cyclophosphamide plus Rituximab (FC-R) for Chronic Lymphocytic Leukaemia

Fludarabine-Cyclophosphamide plus Rituximab (FC-R) for Chronic Lymphocytic Leukaemia DRUG ADMINISTRATION SCHEDULE First Cycle Only: Day Drug Dose Route Diluent Rate 1 Paracetamol 1gram Oral 1 Hydrocortisone 100mg IV bolus 1 Chlorphenamine 10mg IV bolus 1 Rituximab 375mg/m 2 IV infusion

More information

Cetuximab in Combination with Irinotecan based Chemotherapy for the 1 st, 2 nd and 3 rd treatment Metastatic of Colorectal Cancer

Cetuximab in Combination with Irinotecan based Chemotherapy for the 1 st, 2 nd and 3 rd treatment Metastatic of Colorectal Cancer Cetuximab in Combination with Irinotecan based Chemotherapy for the 1 st, 2 nd and 3 rd treatment Metastatic of Colorectal Cancer DRUG ADMINISTRATION SCHEDULE Day Drug Daily Dose Route Diluent and rate

More information

NCCP Chemotherapy Regimen. Brentuximab vedotin Monotherapy

NCCP Chemotherapy Regimen. Brentuximab vedotin Monotherapy INDICATIONS FOR USE: INDICATION Brentuximab Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): Following autologous stem cell transplant (ASCT) or Following at least two

More information

Paclitaxel Gastric Cancer

Paclitaxel Gastric Cancer Systemic Anti Cancer Treatment Handbook Paclitaxel Gastric Cancer PROTOCOL REF: MPHAUGIPAC (Version No: 1.0) Approved for use in: Second line treatment of locally advanced and metastatic gastric / gastro-oesophageal

More information

NECN CHEMOTHERAPY HANDBOOK PROTOCOL

NECN CHEMOTHERAPY HANDBOOK PROTOCOL DRUG ADMINISTRATION SCHEDULE First Cycle: Day Drug Daily Dose Route Diluent & Rate 1 Chlorphenamine 10mg IV bolus 1 Paracetamol 1000mg ORAL 1 Ranitidine 150mg ORAL 1 Dexamethasone 8mg IV bolus 1 Cetuximab

More information

AUSTRALIAN PRODUCT INFORMATION Gazyva (obinutuzumab)

AUSTRALIAN PRODUCT INFORMATION Gazyva (obinutuzumab) AUSTRALIAN PRODUCT INFORMATION Gazyva (obinutuzumab) WARNING Progressive Multifocal Leucoencephalopathy Progressive Multifocal Leukoencephalopathy (PML) including fatal PML can occur in patients receiving

More information

Panobinostat, Bortezomib and Dexamethasone

Panobinostat, Bortezomib and Dexamethasone Panobinostat, Bortezomib and Dexamethasone Indication Treatment of relapsed/refractory multiple myeloma in patients who have received at least 2 prior regimens, including bortezomib and an immunomodulatory

More information

NECN CHEMOTHERAPY HANDBOOK PROTOCOL

NECN CHEMOTHERAPY HANDBOOK PROTOCOL DRUG ADMINISTRATION SCHEDULE First Cycle: Day Drug Daily Dose Route Diluent & Rate 1 Chlorphenamine 10mg IV bolus 1 Paracetamol 1000mg ORAL 1 Ranitidine 150mg ORAL 1 Dexamethasone 8mg IV bolus 1 Cetuximab

More information

Paclitaxel Gynaecological Cancer

Paclitaxel Gynaecological Cancer Systemic Anti Cancer Treatment Protocol Paclitaxel Gynaecological Cancer PROTOCOL REF: MPHAGYNPAC (Version No: 1.0) Approved for use in: Second/ third line option for advanced ovarian cancers (3 weekly

More information

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane

THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane Systemic Anti Cancer Treatment Protocol EDP + mitotane PROCEDURE REF: MPHAHANEDP (Version No: 1.0) Approved for use in: Symptomatic treatment for advanced (unresectable, metastatic or relapsed) adrenocortical

More information

CETUXIMAB Single agent with radiotherapy. PROCEDURE REF: MPHACETUX (Version No: 1.0)

CETUXIMAB Single agent with radiotherapy. PROCEDURE REF: MPHACETUX (Version No: 1.0) Systemic Anti Cancer Treatment Protocol CETUXIMAB Single agent with radiotherapy PROCEDURE REF: MPHACETUX (Version No: 1.0) Approved for use in: Locally advanced squamous cell cancer of the head and neck

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked

More information

ALL MAINTENANCE (25-60 years)

ALL MAINTENANCE (25-60 years) ALL MAINTENANCE (25-60 years) INDICATION Adult Acute Lymphoblastic Leukaemia (ALL) in remission not eligible for allogeneic transplantation This protocol is suitable for patients aged 25-60 years. It may

More information

Burkitt s Lymphoma or DLBCL with adverse features PATIENTS WITH GOOD PERFORMANCE STATUS

Burkitt s Lymphoma or DLBCL with adverse features PATIENTS WITH GOOD PERFORMANCE STATUS Regimen R-CODOX M Indication Burkitt s Lymphoma or DLBCL with adverse features Therapeutic Intent Radical/Curative PATIENTS WITH GOOD PERFORMANCE STATUS Day Medication Dose Route Administration Details

More information

NCCP Chemotherapy Regimen. Brentuximab vedotin Monotherapy

NCCP Chemotherapy Regimen. Brentuximab vedotin Monotherapy Brentuximab INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Status Treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL): Following autologous stem cell

More information

Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)

Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic

More information

FEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel)

FEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel) FEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel) Indication Adjuvant or neo-adjuvant treatment for high risk early and locally advanced breast cancer. (NICE CG80) ICD-10 codes Codes

More information

DERBY-BURTON LOCAL CANCER NETWORK FILENAME ESHAP.DOC CONTROLLED DOC NO: HCCPG B44. ESHAP Regimen

DERBY-BURTON LOCAL CANCER NETWORK FILENAME ESHAP.DOC CONTROLLED DOC NO: HCCPG B44. ESHAP Regimen ESHAP Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication Relapsed/ refractory

More information

Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer

Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer Cisplatin / Capecitabine (+ Trastuzumab) in Gastric Cancer Page 1 of 5 Indication: Confirmed HER2-positive (3+ or FISH+) metastatic adenocarcinoma of the stomach or gastrooesophageal junction. Patient

More information

TCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol

TCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol Systemic Anti Cancer Treatment Protocol TCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol PROTOCOL REF: MPHATCHP (Version No: 1.0) Approved for use in: Neoadjuvant breast: The neoadjuvant

More information

GAZYVA for Chronic Lymphocytic Leukemia (CLL)

GAZYVA for Chronic Lymphocytic Leukemia (CLL) GAZYVA for Chronic Lymphocytic Leukemia (CLL) GAZYVA is a prescription medicine used with the chemotherapy drug, chlorambucil, to treat chronic lymphocytic leukemia (CLL) in adults who have not had previous

More information

BEVACIZUMAB (AVASTIN ) AND XELOX PROTOCOL

BEVACIZUMAB (AVASTIN ) AND XELOX PROTOCOL Bevacizumab (Avastin ) for the first line treatment of advanced colorectal cancer with XELOX DRUG ADMINISTRATION Day Drug Daily Dose Route Diluent & Rate Day 1 Bevacizumab 7.5mg/kg Infusion Day 1 Days

More information